Antibiotice SAATB:BUH

0.514
0.00 / 0.00%
1.63k
14.33 %
0.473
Close in RONToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 05 2016 15:15 GMT.

About the company

316.90m23.48m19911.47k
Revenue in RON (TTM)Net income in RONIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
Antibiotice SA
Str. Valea Lupului nr.1
IASI707410
Romania
ROU
Phone+40 232209583Fax+40 232209633Websitehttp://www.antibiotice.ro/
Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.

Mergers & acquisitions

There are no recent mergers or acquisitions for Antibiotice SA.
Data delayed at least 15 minutes, as of Feb 05 2016 15:15 GMT.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Midatech Pharma PLC
2.60m-63.72m338.90m38--1.30--130.49-0.7268-0.72680.0231.340.0193--0.525111,710.53-47.4417---53.8615-------2,453.483-----242.18370.0436--6.80---116.0137------
Faron Pharmaceuticals Oy
4.28m-14.14m340.60m----57.15--79.63-0.0975-0.09750.02950.0442----------------73.79---330.608--1.56-23.0620.5418--353.00--9.55------
Bioventix PLC
25.29m14.93m342.70m1323.358.9222.5613.550.49780.49780.84371.300.68411.792.21333,32540.3740.1543.2040.1592.6091.6259.0253.6820.91--0.0056.4622.5722.3940.8735.2829.49--
OptiBiotix Health PLC
0-7.40m363.18m5--0.0687-----7.3155-7.31550.0011.860.00-------51.0013---51.5933--------------0.00--------------
Oxford Pharmascience Group Plc
4.15m-19.23m369.43m11--2.57--89.03-0.0033-0.00330.00070.02050.042223.071.1564,636.36-19.5437-36.7668-19.9359-36.766827.0031.90-463.2911-263.800470.94--0.00---31.486966.99-92.6026---24.2142--
Antibiotice SA
316.90m23.48m345.07m1.47k14.910.95028.641.090.03450.03450.4720.54090.59821.801.20216,3114.437.126.177.1262.8869.717.418.341.8011.030.174239.940.47647.62-0.771621.1849.5245.64
BioPorto A/S
11.73m-6.71m351.51m24--11.47--29.96-0.0932-0.09320.15210.39330.4047--1.75813,000-23.1469-83.5425-28.3756-83.542574.0241.16-57.1905-91.7861---61.9770.002--12.5111.1940.90--124.98--
Hansa Medical AB
2.41m-28.49m334.30m18--3.06--138.95-2.0279-2.02790.17337.100.033----361,571-39.0912-49.6411-41.0374-49.6411-138.1272---1,183.979-909.1816---13.05890.0004---6.3115-11.5205-65.3684------
Immunicum AB
0-17.71m346.54m5--12.83-----1.8714-1.87140.002.840.00----0.00-45.6229-37.9005-48.8394-37.9005-------1,311,776.00----0.0147-------120.1826------
Active Biotech AB
6.75m-99.68m358.96m55--2.92--53.19-2.5259-2.52590.16772.870.0265--1.76253,554-39.1067-32.3224-44.7172-32.3224-----1,476.245-155.646---31.30490.4575---91.033-0.7023-9.1595--92.46--
Photocure ASA
59.15m-27.36m355.39m47--3.48--6.01-2.7351-2.73515.9010.150.45510.55946.002,684,830-21.0484-4.0425-23.2759-4.042593.6593.21-46.248-11.93425.82--0.00--54.2221.6457.88--3.07--
Moberg Pharma AB
131.35m11.83m364.91m3331.432.1921.742.781.721.7219.7424.660.7334.545.109,212,0006.60-0.10077.73-0.100775.6875.049.00-0.12941.8045.650.0189--27.19162.17208.01--12.72--
Weifa ASA
152.45m12.29m371.87m6818.170.602520.012.440.04790.0340.60621.440.19921.503.504,782,4271.61-15.72791.74-15.727970.16--8.06-88.78884.781.480.2286--19,153.0275.99338.44------
Data as of Feb 06 2016. Currency figures normalised to Antibiotice SA's reporting currency: .
Data delayed at least 20 minutes, as of Feb 05 2016 20:59 GMT.

Institutional shareholders

HolderShares% Held
Oltenia SIF SA (Investment Management)
as of 30 Jun 2015
92.56m13.13%
Transilvania SIF SA (Invt Mgmt)
as of 30 Sep 2014
27.09m3.84%
Banat-Crisana SIF SA (Investment Management)
as of 30 Sep 2014
14.17m2.01%
Financial Investment Company Moldova SA (Invt Mgmt)
as of 30 Jun 2014
3.32m0.47%
Parametric Portfolio Associates LLC
as of 30 Nov 2015
3.15m0.45%
St. Galler Kantonalbank AG (Private Banking)
as of 31 Aug 2015
2.66m0.38%
Erste Asset Management SAI SA
as of 30 Jun 2015
2.33m0.33%
Danske Bank A/S (Invt Mgmt)
as of 31 Dec 2015
1.98m0.28%
BT Asset Management SAI SA
as of 30 Jun 2015
1.24m0.18%
Globinvest SAI SA
as of 30 Jun 2015
1.10m0.16%
21.22%
Per cent of shares
held by top holders
Data from 31 Dec 2014 - 31 Dec 2015Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.